Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

05-02-2016 | Non-melanoma skin cancer | Article

Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face

Journal: Head & Face Medicine

Authors: L. Feller, R. A. G. Khammissa, B. Kramer, M. Altini, J. Lemmer

Publisher: BioMed Central

Login to get access

Abstract

Ultraviolet light (UV) is an important risk factor for cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma and cutaneous melanoma of the skin. These cancers most commonly affect persons with fair skin and blue eyes who sunburn rather than suntan. However, each of these cancers appears to be associated with a different pattern of UV exposure and to be mediated by different intracellular molecular pathways.
Some melanocortin 1 receptor (MC1R) gene variants play a direct role in the pathogenesis of cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma and cutaneous melanoma apart from their role in determining a cancer-prone pigmentory phenotype (fair skin, red hair, blue eyes) through their interactions with other genes regulating immuno-inflammatory responses, DNA repair or apoptosis.
In this short review we focus on the aetiological role of UV in cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma and cutaneous melanoma of the skin, and on some associated biopathological events.
Literature
1.
Brash DE, Heffernan T, Ngheim P. Carcinogenesis: Ultravoilet radiation. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine, vol. 1. New York: McGraw-Hill; 2008. p. 999–1006.
2.
Donovan J. Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatol Surg. 2009;35(9):1311–23.CrossRefPubMed
3.
Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, Achouri Y, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12(3):299–305.PubMed
4.
Tlholoe MM, Khammissa RA, Bouckaert M, Altini M, Lemmer J, Feller L. Oral Mucosal Melanoma: Some Pathobiological Considerations and an Illustrative Report of a Case. Head Neck Pathol. 2015;9(1):127–34.CrossRefPubMed
5.
Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–54.CrossRefPubMedPubMedCentral
6.
Dlugosz AA, Yuspa SH. Carcinogenesis: Chemical. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine, vol. 1. New York: McGraw-Hill; 2008. p. 986–95.
7.
Grossman D, Leffell DJ. Squamous cell carcinoma. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine, vol. 1. New York: McGraw-Hill; 2008. p. 1028–36.
8.
Scherer D, Kumar R. Genetics of pigmentation in skin cancer--a review. Mutat Res. 2010;705(2):141–53.CrossRefPubMed
9.
Hoban PR, Ramachandran S, Strange RC. Environment, phenotype and genetics: risk factors associated with BCC of the skin. Expert Rev Anticancer Ther. 2002;2(5):570–9.CrossRefPubMed
10.
Riker AI, Zea N, Trinh T. The epidemiology, prevention, and detection of melanoma. Ochsner J. 2010;10(2):56–65.PubMedPubMedCentral
11.
Carucci JA, Lefell DJ. Basal cell carcinoma. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine, vol. 1. New York: McGraw-Hill; 2008. p. 1036–42.
12.
Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene. 2003;22(20):3099–112.CrossRefPubMed
13.
Nan H, Kraft P, Hunter DJ, Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer. 2009;125(4):909–17.CrossRefPubMedPubMedCentral
14.
Feller L, Masilana A, Khammissa RA, Altini M, Jadwat Y, Lemmer J. Melanin: the biophysiology of oral melanocytes and physiological oral pigmentation. Head Face Med. 2014;10(1):8.CrossRefPubMedPubMedCentral
15.
Palmer RM, Cortellini P. Group BoEWoP. Periodontal tissue engineering and regeneration: Consensus Report of the Sixth European Workshop on Periodontology. Journal of Clinical Periodontology. 2008;35(8 Suppl):83–6.CrossRefPubMed
16.
Han J, Kraft P, Colditz GA, Wong J, Hunter DJ. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer. 2006;119(8):1976–84.CrossRefPubMed
17.
Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, et al. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer. 2010;116(10):2416–28.PubMedPubMedCentral
18.
Feller L, Altini M, Lemmer J. Inflammation in the context of oral cancer. Oral Oncol. 2013;49(9):887–92.CrossRefPubMed
19.
Scherer D, Bermejo JL, Rudnai P, Gurzau E, Koppova K, Hemminki K, et al. MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer. 2008;122(8):1787–93.CrossRefPubMed
20.
Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol. 2001;117(2):294–300.CrossRefPubMed
21.
Hauser JE, Kadekaro AL, Kavanagh RJ, Wakamatsu K, Terzieva S, Schwemberger S, et al. Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment Cell Res. 2006;19(4):303–14.CrossRefPubMed
22.
Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R, Kadekaro AL, Swope V, Haskell-Luevano C, et al. alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Melanoma Res. 2009;22(5):635–44.CrossRefPubMed
23.
Rizzato C, Scherer D, Rudnai P, Gurzau E, Koppova K, Hemminki K, et al. POMC and TP53 genetic variability and risk of basal cell carcinoma of skin: Interaction between host and genetic factors. J Dermatol Sci. 2011;63(1):47–54.CrossRefPubMed
24.
Dong L, Wen J, Pier E, Zhang X, Zhang B, Dong F, et al. Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism. Cancer Res. 2010;70(9):3547–56.CrossRefPubMedPubMedCentral
25.
Song X, Mosby N, Yang J, Xu A, Abdel-Malek Z, Kadekaro AL. alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res. 2009;22(6):809–18.CrossRefPubMed
26.
Ghanem G, Fabrice J. Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. Mol Oncol. 2011;5(2):150–5.CrossRefPubMedPubMedCentral
27.
Melnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res. 2005;571(1–2):91–106.CrossRefPubMed
28.
Sinha RP, Hader DP. UV-induced DNA damage and repair: a review. Photochem Photobiol Sci. 2002;1(4):225–36.CrossRefPubMed
29.
Andreassi L. UV exposure as a risk factor for skin cancer. Expert Review of Dermatology. 2011;6(5):445–54.CrossRef
30.
Wood NH, Khammissa R, Meyerov R, Lemmer J, Feller L. Actinic cheilitis: a case report and a review of the literature. Eur J Dent. 2011;5(1):101–6.PubMedPubMedCentral
31.
Feller L, Khammissa RAG, Kramer B, Lemmer J. Oral squamous cell carcinoma in relation to field precancerisation: pathobiology. Cancer Cell Int. 2013;13(1):31.CrossRefPubMedPubMedCentral
32.
Feller L, Lemmer J. New 'second primary' cancers. SADJ. 2012;67(4):175–8.PubMed
33.
Feller L, Khammissa RA, Wood NH, Jadwat Y, Meyerov R, Lemmer J. Sunlight (actinic) keratosis: an update. J Prev Med Hygiene. 2009;50(4):217–20.
34.
Tamamura R, Nagatsuka H, Siar CH, Katase N, Naito I, Sado Y, et al. Comparative analysis of basal lamina type IV collagen alpha chains, matrix metalloproteinases-2 and −9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem. 2013;115(2):113–9.CrossRefPubMed
35.
de Oliveira Poswar F, de Carvalho Fraga CA, Gomes ES, Farias LC, Souza LW, Santos SH, et al. Protein expression of MMP-2 and MT1-MMP in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma. Int J Surg Pathol. 2015;23(1):20–5.CrossRefPubMed
36.
de Vicente JC, Fresno MF, Villalain L, Vega JA, Hernandez VG. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol. 2005;41(3):283–93.CrossRefPubMed
37.
Martins VL, Vyas JJ, Chen M, Purdie K, Mein CA, South AP, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009;122(Pt 11):1788–99.CrossRefPubMedPubMedCentral
38.
Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316(17):2713–22.CrossRefPubMed
39.
Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol. 2010;21(1):19–25.CrossRefPubMedPubMedCentral
40.
Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell carcinoma (Review). Oncol Lett. 2014;8(1):7–11.PubMedPubMedCentral
41.
Jung DW, Che ZM, Kim J, Kim K, Kim KY, Williams D, et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int J Cancer. 2010;127(2):332–44.PubMed
42.
Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, et al. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res. 2013;73(13):4147–57.CrossRefPubMed
43.
Ramachandran S, Fryer AA, Smith AG, Lear JT, Bowers B, Griffiths CE, et al. Basal cell carcinoma. Cancer. 2000;89(5):1012–8.CrossRefPubMed
44.
Danaee H, Karagas MR, Kelsey KT, Perry AE, Nelson HH. Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin. J Invest Dermatol. 2006;126(5):1152–8.CrossRefPubMed
45.
Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet. 2001;10(7):757–62.CrossRefPubMed
46.
Heitzer E, Lassacher A, Quehenberger F, Kerl H, Wolf P. UV fingerprints predominate in the PTCH mutation spectra of basal cell carcinomas independent of clinical phenotype. J Invest Dermatol. 2007;127(12):2872–81.CrossRefPubMed
47.
Chinem VP, Miot HA. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011;86(2):292–305.CrossRefPubMed
48.
Wong SY, Dlugosz AA. Basal cell carcinoma, Hedgehog signaling, and targeted therapeutics: the long and winding road. J Invest Dermatol. 2014;134(e1):E18–22.CrossRefPubMed
49.
Boehnke K, Falkowska-Hansen B, Stark HJ, Boukamp P. Stem cells of the human epidermis and their niche: composition and function in epidermal regeneration and carcinogenesis. Carcinogenesis. 2012;33(7):1247–58.CrossRefPubMed
50.
Cho E, Rosner BA, Colditz GA. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1241–4.CrossRefPubMed
51.
Radespiel-Troger M, Meyer M, Pfahlberg A, Lausen B, Uter W, Gefeller O. Outdoor work and skin cancer incidence: a registry-based study in Bavaria. Int Arch Occup Environ Health. 2009;82(3):357–63.CrossRefPubMed
52.
Feller L, Wood NH, Motswaledi MH, Khammissa RA, Meyer M, Lemmer J. Xeroderma pigmentosum: a case report and review of the literature. J Prev Med Hygiene. 2010;51(2):87–91.
53.
Elwood JM, Gallagher RP. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int J Cancer. 1998;78(3):276–80.CrossRefPubMed
54.
Situm M, Bolanca Z, Buljan M. Lentigo maligna melanoma--the review. Coll Antropol. 2010;34 Suppl 2:299–301.PubMed
55.
Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003;95(11):806–12.CrossRefPubMed
56.
Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet. 2000;66(1):176–86.CrossRefPubMed
57.
Maddodi N, Setaluri V. Role of UV in cutaneous melanoma. Photochem Photobiol. 2008;84(2):528–36.CrossRefPubMed
58.
Paek SC, Sober AJ, Tsao H, Mihm MCJ, Johnson AD. Cutaneous melanoma. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine, vol. 1. New York: McGraw-Hill; 2008. p. 1134–57.
59.
Terenziani M, Spreafico F, Serra A, Podda M, Cereda S, Belli F. Amelanotic melanoma in a child with oculocutaneous albinism. Med Pediatr Oncol. 2003;41(2):179–80.CrossRefPubMed
60.
George AO, Ogunbiyi AO, Daramola OO, Campbell OB. Albinism among Nigerians with malignant melanoma. Trop Doct. 2005;35(1):55–6.PubMed
61.
Gidanian S, Mentelle M, Meyskens Jr FL, Farmer PJ. Melanosomal damage in normal human melanocytes induced by UVB and metal uptake--a basis for the pro-oxidant state of melanoma. Photochem Photobiol. 2008;84(3):556–64.CrossRefPubMed
62.
Pavel S, van Nieuwpoort F, van der Meulen H, Out C, Pizinger K, Cetkovska P, et al. Disturbed melanin synthesis and chronic oxidative stress in dysplastic naevi. Eur J Cancer. 2004;40(9):1423–30.CrossRefPubMed
63.
Slavin S. Effector cells of experimental and clinical cellular adoptive immunobiology. In: Morstyn G, Sheridan W, editors. Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy. Los Angeles: Cambridge University Press; 1996. p. 18–42.
64.
Welsh MM, Karagas MR, Applebaum KM, Spencer SK, Perry AE, Nelson HH. A role for ultraviolet radiation immunosuppression in non-melanoma skin cancer as evidenced by gene-environment interactions. Carcinogenesis. 2008;29(10):1950–4.CrossRefPubMedPubMedCentral
65.
Murphy GM. Ultraviolet radiation and immunosuppression. Br J Dermatol. 2009;161 Suppl 3:90–5.CrossRefPubMed